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Abstract
Background: Fibroblast growth factor 21 (FGF21) increases glucose uptake. It is unknown if FGF21 serum levels are affected
by exercise.
Methodology/Principal Findings: This was a comparative longitudinal study. Anthropometric and biochemical evaluation
were carried out before and after a bout of exercise and repeated after two weeks of daily supervised exercise. The study
sample was composed of 60 sedentary young healthy women. The mean age was 2463.7 years old, and the mean BMI was
21.467.0 kg/m
2. The anthropometric characteristics did not change after two weeks of exercise. FGF21 levels significantly
increased after two weeks of exercise (276.8 ng/l (142.8–568.6) vs. (460.8 (298.2–742.1), p,0.0001)). The delta (final–basal)
log of serum FGF21, adjusted for BMI, showed a significant positive correlation with basal glucose (r=0.23, p=0.04), mean
maximal heart rate (MHR) (r=0.54, p,0.0001), mean METs (r=0.40, p=0.002), delta plasma epinephrine (r=0.53, p,0.0001)
and delta plasma FFAs (r=0.35, p=0.006). A stepwise linear regression model showed that glucose, MHR, METs, FFAs, and
epinephrine, were factors independently associated with the increment in FGF21 after the exercise program (F=4.32;
r
2=0.64, p,0.0001).
Conclusions: Serum FGF21 levels significantly increased after two weeks of physical activity. This increment correlated
positively with clinical parameters related to the adrenergic and lipolytic response to exercise.
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Introduction
Fibroblast growth factor 21 (FGF21) is a protein involved in
glucose uptake, lipid metabolism and energy balance [1]. It is
synthesized in the liver [2] and secreted following the agonist effect
of free fatty acids (FFAs) on peroxisome proliferator-activated
receptor alpha nuclear receptors (PPAR-alpha) [3]. It plays an
important role in the adaptation to fasting in animal models.
FGF21 has diverse effects including the stimulation of gluconeo-
genesis, fatty acid oxidation, lipolysis, ketogenesis [4], inhibition of
lipogenesis [5] and blunting of the GH-signaling pathway [6].
FGF21 also increases glucose utilization (through the Akt pathway)
in fat and muscle [7]. This hormone appears to improve the
utilization of energy substrates (fatty acids, ketones, and glucose),
and interferes with energy consuming processes (i.e. lipogenesis
and growth). However, in humans under physiological conditions,
its functions are still not clear. In clinical studies, a positive
correlation between FGF21 plasma levels and many parameters of
obesity (e.g. body mass index (BMI), waist circumference, waist to
hip ratio and fat percentage) has been shown [8]). Our group has
found a direct relationship between FGF21 and BMI, uric acid,
fasting glucose, and the components of the metabolic syndrome
[9]). We identified a direct relationship (r=0.23, p=0.002)
between daily physical activity and serum FGF21 levels. Increased
FFAs concentration may be the mechanism explaining the
observed associations. Therefore, we hypothesized that serum
FGF21 levels will increase after an exercise program. To confirm
this theory, we carried out this longitudinal study to evaluate the
impact of a two week supervised intensive physical activity
program on serum FGF21 levels, in a group of young sedentary
healthy women.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
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The Human Biomedical Research Institutional Committee of
our Institution approved the study, and written informed consent
was obtained from all subjects. All clinical investigation was
conducted according to the principles expressed in the Declaration
of Helsinki.
Study aims
The aim of the study was to evaluate the impact of a two week
supervised intensive physical activity program on serum FGF21
levels, in a group of young sedentary healthy women. In order to
discuss the possible mechanisms involved, the secondary outcomes
of the study were to evaluate the association between FGF21 and
free fatty acids (FFAs), metabolic equivalents (METs) and
epinephrine, after a single bout of exercise and after the two
week exercise program.
Participants
Between March 2010 and August 2011 a total of 63 sedentary
young women aged 18 to 35 years old, with a BMI ,30 kg/m
2,
and without any contraindication for exercising, were included in
the study. Subjects were nutritionist and medical students
participating in a clinical rotation at the Department of
Endocrinology of the Instituto Nacional de Ciencias Me ´dicas y
Nutricio ´n Salvador Zubira ´n (INCMNSZ). In addition, partici-
pants’ sisters were also invited. We included 3 participants every 2
Figure 1. Flow chart of the study protocol.
doi:10.1371/journal.pone.0038022.g001
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because the lipolytic response after exercising is higher in women
than in men [10]. Furthermore, women have lower cardiovascular
risk with intensive physical activity than men. Sedentary lifestyle
was defined as an absence of moderate to vigorous regular physical
activity during the previous 6 months [11]. We excluded subjects
with the metabolic syndrome, diabetes, dyslipidemia, hyperten-
sion, asthma, and thyroid disease. In addition, women treated with
fibrates, beta agonists or blockers, a past or present history of
arrhythmias, murmurs, cardiomegaly, or treatment for cardiovas-
cular diseases were excluded. Contraindications for exercise testing
were also considered as exclusion criteria [12]. The flow chart of
the study protocol is showed in figure 1.
Study protocol
This was an interventional study of one group and every subject
was used as its own control. All subjects underwent a basal and
final physical examination. The routine biochemical analyses were
carried out after overnight fasting between 8 to 12 h. In the initial
visit, patients were instructed not to alter their diet, lifestyle and
level of physical activity. Basal daily physical activity was evaluated
with a questionnaire developed by Tremblay et al and validated in
the Mexican population [13]. The questionnaire quantifies
physical activity level (kcal/day or in kJ if kcal are multiplied by
4.1855) throughout a 24hr-day as previously described [9]. In
brief, every subject answered three questionnaires distributed over
two labor days and one day of the weekend. These results were
added together and the average kcal/day was obtained. The
participants answered the questionnaires at the beginning and end
of the study.
A treadmill exercise test (following the Bruce’s protocol) was
carried out five times a week (from Monday to Friday) for two
weeks. The Bruce protocol is a multistage, well standardized test,
which includes electrocardiographic monitoring during exercise
[12]). The protocol has seven stages, each lasting three minutes,
resulting in 21 minutes’ of exercise for a complete test. In stage 1,
patients walk at 1.7 mph (2.7 km) up a 10% incline. Energy
expenditure is estimated to be 4.8 metabolic equivalents (METs)
during this stage. The speed and inclination is increased in each
stage. From the second to the seventh stage, the speed increases
from 2.5 mph (4.0 km/hr) to 6.0 mph (9.6 km/hr), and inclina-
tion from 12 to 22%; METs increase from 7.0 to 22.0,
respectively. Assessment of workload is measured by METs which
is an indirect reflection of oxygen consumption and energy use.
One MET is 3.5 ml oxygen/kg per minute, which is the oxygen
consumption of an average individual at rest. To carry out the
activities of daily living an exercise intensity of at least 5 METs is
required [12]. By convention, the maximum predicted heart rate is
calculated as 220 (210 for women) minus the subject’s age. A
satisfactory heart rate response is achieved on reaching 85% of the
maximum predicted heart rate [12]. Therefore, we maintained the
heart rate above an intensity of 85% for at least 15 minutes in
each test. The first exercise test was carried out in the morning
between 7–8:30 AM. Participants were given the option of
appointments between 7:00 to 8:30 AM or between midday and
14 hrs depending on the availability of the treadmill and to favor
adherence for subsequent tests. Although most participants came
at same hour every day, sometimes they accomplished with the
study running in the other schedule. We considered two criteria
for stopping the test: 1) when a participant reached her maximum
predicted heart rate to reduce the probability of adverse events;
and 2) because of fatigue. Systolic (SBP) and diastolic (DBP) blood
pressure were measured before (at rest) and during (at two minutes
intervals) in each test.
The study had a duration of 2 weeks with a total of 9 tests.
Additional physical activity was prohibited. Participants with one
missing test in the second week of exercising were eliminated from
the study (n=3, 4.7%).
Glucose, insulin, FFAs, FGF21, and leptin plasma levels were
measured before and at 1 and 4 hours after the first exercise test to
evaluate the acute impact of exercise. This sampling schedule was
based on the effects of elevated FFAs on FGF21 in humans 14].
During this time period, participants remained fasting.
Biochemical and anthropometric measurements
The Department of Endocrinology and Metabolism at the
INCMNSZ performed all biochemical laboratory measurements
using standardized procedures. The measurements were per-
formed with commercially available standardized methods.
Glucose was measured using the glucose oxidase method
(Boehringer Mannheim, Germany), serum total cholesterol and
triglycerides were measured using an enzymatic method (Beck-
Table 1. Clinical and biochemical parameters of the sample
studied before and after two weeks of supervised physical
activity (n=60).
Variables Before After p value
Age (yr) 24.063.7 - -
SBP (mmHg) 101.3610.0 100.468.8 0.38
DBP (mmHg) 65.766.1 64.966.1 0.32
BMI (kg/m
2) 21.467.0 21.367.0 0.14
Waist circumference (cm) 74.668.0 74.367.9 0.12
Hip circumference (cm) 91.666.0 92.3611.7 0.59
WHR 0.8160.05 0.8160.07 0.57
Fat percentage (%) 27.665.5 28.669.1 0.23
Free fat mass (gr/kg) 35.763.1 35.5630.1 0.12
ALT (IU/l) 14.466.6 14.265.2 0.78
AST (IU/l) 20.164.9 19.063.9 0.05
GGT (IU/l) 13.0 (11.0–17.7) 12.0
(11.0–16.0)
0.004
Cholesterol (mg/dl) 171.5638.5 171.9634.2 0.90
Triglycerides (mg/dl) 101.5 (66.0–139.2) 75.5
(60.2–99.7)
0.001
HDL-C (mg/dl) 52.4612.9 53.2613.6 0.27
LDL-C (mg/dl) 99.2624.7 99.8625.9 0.75
Uric acid (mg/dl) 4.460.9 4.460.9 0.95
Serum creatinine (mg/dl) 0.6660.11 0.6560.09 0.30
Daily physical activity
(kcal/day)*
1453 (1229–1660) 4359 (3688–
4982)
,0.0001
Number of tests, n (%)
6 - 6 (10) -
7 - 15 (25) -
8 - 10 (16.7) -
9 - 29 (48.3) -
Data are expressed as mean6SD or as median (interquartil range). NS=not
significant. SBP=systolic blood pressure; DBP=diastolic blood pressure;
BMI=body mass index; WHR=waist-hip-ratio; ALT=alanine aminotransfarase;
AST=aspartate aminotransferase; LDL-C=low-density lipoprotein cholesterol;
HDL-C=high-density lipoprotein cholesterol; GGT=gamma-
glutamyltransferase.
*Daily physical activity measured with questionnaire.
doi:10.1371/journal.pone.0038022.t001
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precipitation using phosphotungstic acid and Mg2
+ (Beckman),
plasma insulin was determined by monoclonal assay (MEIA,
Abbott Laboratories), and creatinine and uric acid were measured
using commercially available kit (Beckman Coulter, Inc.). All
equipment was regularly calibrated using reference samples
provided by the manufacturer. A human FGF21 ELISA kit was
used (BioVendor Laboratory Medicine, Modrice, Czech Republic)
following the procedure described previously [9]. Serum adipo-
nectin and leptin (Millipore, Mexico), free fatty acids (Wako
Chemicals, USA), and adrenaline (MP Biomedicals, USA) were
determined by a sandwich ELISA kit. Anthropometric measure-
ments were carried out after participants removed their shoes and
upper garments. Body weight and fat was quantified with the UM-
026 Tanita Body Composition Analyzer (Tanita, Tokyo). All
subjects were instructed to stand in the centre of the scale during
weight assessment. Height was obtained using the floor scale’s
stadiometre, again with the patient standing on the central part of
the scale. Height was measured to the nearest 0.5 cm. BMI was
calculated as weight (kg) divided by height (m
2). Abdominal
circumference was measured to the nearest 0.1 cm at the level of
the greatest frontal extension of the abdomen between the bottom
of the rib cage and the top of the iliac crest.
Statistical analysis
The sample size was calculated using the formula for means for
two-tailed comparisons. According to our previous report [9], we
expected a minimal change of 80 ng/l of FGF21 after two weeks
of physical activity. Using a SD of 160 ng/l with an alfa of 0.05
and a study power of 80%, a total of 60 subjects were calculated.
All participants were included in each statistical analysis. Normally
distributed data, determined using Kolmogorov-Smirnov test,
were expressed as means and standard deviation (6SD), whereas
variables with a skewed distribution were reported as median
(interquartile range) and log transformed to approximate normal-
ity before analyses. Chi Square, Student’s unpaired t test,
Wilcoxon signed rank test or Mann-Whitney U test was used as
appropriate for comparison of measurements before and after
physical activity. Homogeneity of variance was evaluated with
Levene’s test. For data collected at multiple time points we used
repeated measures analysis with effects for time. Sphericity was
evaluated with Mauchly’s test. When necessary, correction of
significance with Greenhouse-Geisser or Huynh-Feldt epsilon was
applied. Pairwaise comparisons between time points were done
based on estimated marginal means. Bonferroni correction was
used for adjustment for multiple comparisons. Correlation
coefficients between FGF21 and continuous variables were
evaluated in all participants, and were calculated using the
Spearman’s rho, Pearson’s r tests or using partial correlation
analysis when adjusted for BMI. Kruskall-Wallis test or one-way
ANOVA were used for comparing continuous variables of patients
stratified by tertiles of serum levels of FGF21. To evaluate the
effect of exercise on clinical and biochemical parameters, we used
the difference between final – basal levels (as indicated with
‘‘delta’’). ‘‘Resting’’ refers to the value obtained before each test.
‘‘Maximum’’ refers to the highest value obtained during each test.
Mean refers to the sum of values/number of tests. We calculated
the mean of resting and maximum heart rate, systolic and diastolic
blood pressure as specified. A stepwise linear regression model was
used to examine the impact of variables in delta log serum FGF21
levels (model 1) and delta FFAs (model 2). Homogeneity and
linearity were confirmed through the pattern of studentized
residuals plotted against adjusted predicted values. The variables
selected for the regression analyses were those that correlated
significantly with serum FGF21 or FFAs and those that have been
shown to be associated with plasma levels of these proteins [4,9].
Table 2. Comparisons of biochemical parameters before and after supervised physical activity (n=60).
Parameter
Time N
Glucose
(mg/dl)
Insulin
(mU/ml)
FGF21
(ng/l)
FFA
(mg/dl)
Epinephrine
(pg/ml)
Leptin
(ng/ml)
Adiponectin
(ng/ml)
Baseline 60 86.067.1 8.1 (5.7–11.1) 276.8 (142.8–
568.6)
0.36 (0.24–
0.44)
9.2 (5.9–12.1) 13.1 (8.7–21.1) 10.1 (8.0–13.4)
1 hr after first bout of
exercise
60 89.8612.2 10.8 (6.4–13.3) 237.0 (134.0–
581.2)
0.34 (0.22–
0.47)
10.0 (7.6–14.6) 11.6 (8.3–16.8) 9.9 (8.2–13.3)
4 hr after first bout of
exercise
42 85.569.2 9.6 (6.3–12.9) 268.9 (192.8–
582.8)
0.29 (0.15–
0.41)
10.5 (5.9–14.1) 12.1 (7.8–15.9) 10.3 (8.2–13.2)
Final (after 2 weeks) 60 86.366.4 7.9 (5.4–10.2) 460.8 (298.2–
742.1)
0.54 (0.43–
0.66)
15.5 (11.3–18.8) 12.4 (10.0–16.2) 10.5 (8.0–13.2)
p values* p values adjusted for age, BMI, WC, glucose and insulin*
Basal vs. 1 hr 60 0.177 0.621 1.00 1.00 0.005 ,0.0001 0.341
Basal vs. 4 hr 42 0.021 ,0.0001 1.00 1.00 0.043 ,0.0001 0.386
Basal vs. Final 60 1.00 0.41 ,0.0001 ,0.001 ,0.0001 0. 16 1.00
1 hr vs. 4 hr 42 0.609 ,0.0001 1.00 1.00 0.267 0.492 1.00
1 hr vs. Final 60 0.346 0.086 ,0.0001 ,0.055 ,0.0.04 0.882 0.909
4 hr vs. Final 42 0.029 ,0.0001 ,0.0001 ,0.0001 ,0.0001 0.038 0.578
Time effects 60 0.002 ,0.0001 0.003 0.029 0.049 0.273 0.613
Data are expressed as mean6SD or as median (interquartil range). FGF21 was log-transformed before analysis. NS=not significant. BMI=body mass index; WC=waist
circumference; FFAs=free fatty acids.
*Bonferroni adjustment for multiple comparisons. Parameters of the repeated measures model of: Glucose: Hotteling’s trace=0.33; F=3.29; p=0.034; Insulin:
Hotteling’s trace=1.80; F=18.01; p,0.0001; FGF21: Hotteling’s trace=2.62; F=22.76; p,0.0001; FFAs: Hotteling’s trace=1.58; F=13.2; p,0.0001; Leptin: Hotteling’s
trace=0.96; F=10.93; p,0.0001; Epinephrine: Hotteling’s trace=2.29; F=19.13; p,0.0001; Adiponectin: Hotteling’s trace=0.17; F=1.98; p=0.135.
doi:10.1371/journal.pone.0038022.t002
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#0.05 as significant. All analyses were performed with SPSS 17.0
(Chicago, IL).
Results
A total of 60 women with a mean age of 24.063.7 years and a
mean BMI of 21.467.0 kg/m2 were evaluated. The baseline and
final characteristics of the study population are shown in Table 1.
The anthropometric data of participants did not change after two
weeks of physical activity. Significant reductions in triglyceride and
gamma glutamyltransferase (GGT) plasma levels were observed
following the exercise program (Table 1). The median (interquartil
range) of daily physical activity at baseline quantified with the
questionnaire was 1453.2 (1229.4–1660.8) kcal/day. After two
weeks, an expected and significant increment in kcal/day was
identified (4359.6 (3688.3–4982.5), p,0.0001).
Almost half of the participants completed the 9 scheduled tests.
The remaining 16.7%, 25%, and 10% completed 8, 7 and 6 tests,
respectively (Table 1). The mean duration of the exercise tests was
14.261.4 minutes per session. The majority of participants
reached the stage 4 of the Bruce’s protocol, with a mean METs
consumption of 12.262.4. Tolerance to exercise increased during
the study. The mean duration of exercise in the first week (tests 1
to 5) was of 14.061.6 minutes per session. This time increased
significantly in the second week (14.561.5 min, p=0.002).
Similarly, the METs consumed in the second week were greater
(12.262.3) than in the first (11.362.5, p,0.0001).
At baseline, log serum FGF21 levels correlated positively with
FFA (r=0.12, p=0.03), fasting glucose (r=0.29, p=0.04) and
physical activity (r=0.16, p=0.05), and negatively with adipo-
nectin (r=20.27, p=0.03), and creatinine (r=20.25, p=0.04).
FFAs correlated positively with fasting glucose (r=0.30, p=0.02)
and negatively with baseline insulin (r=20.31, p=0.01). No
significant correlation was identified between log FGF21 and
fasting insulin (r=0.17, p=0.17).
Acute effects of exercise on FGF21
The baseline levels of glucose, insulin, FGF21, FFA, epineph-
rine, leptin and adiponectin were compared with their corre-
sponding levels at one and four hours following the first exercise
session (table 2). At one hour, no significant changes in glucose and
insulin were documented. At the fourth hour, glucose was reduced
to a level below baseline (p=0.021) and insulin showed a
significant increment in comparison with the baseline levels
(p=0.0001). A significant increment in adrenaline and a
significant reduction in leptin was also documented (all p,0.05).
However, acute exercise did not change the serum levels of FFAs,
FGF21, and adiponectin (table 2).
Change in FGF21 levels after two weeks of exercising
After two weeks of exercising there was a significant increase in
serum FGF21 (276.8 (142.8–568.6) vs. 460.8 (298.2–742.1) ng/l,
p,0.0001), and FFAs values (0.36 (0.24–0.44) vs. 0.54 (0.43–0.66)
mg/dl, p,0.001). No significant changes were identified in serum
leptin or adiponectin levels.
The delta of log serum FGF21, had a significant positive
correlation with delta epinephrine (r=0.53, p,0.0001), METs
consumption (r=0.40, p,0.0001), and delta FFA levels (r=0.35,
p,0.0001, figure 2). Similar results were obtained after adjust-
ment for BMI. The mean resting (r=0.43, p,0.0001) and
maximum (r=0.54, p,0.0001) heart rate also correlated posi-
tively with delta log FGF21 (table 3). Additionally, subjects in the
second and third tertile of the delta log FGF21 had a higher level
Figure 2. Correlation of the log delta FGF21 (final-basal) levels
with METs (A), delta epinephrine (B), and delta free fatty acids
(C) in 60 women after two weeks of supervised physical
activity.
doi:10.1371/journal.pone.0038022.g002
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rate (MHR, p,0.0001), mean METs (p=0.008), delta FFAs
(p=0.01), delta epinephrine (p=0.008), and mean maximum
systolic (p=0.05) and diastolic (p=0.01) blood pressure in
comparison with the first tertile (table 4). No significant association
was identified with anthropometric parameters, resting blood
pressure and delta leptin levels with tertiles of delta log FGF21.
Delta FFAs correlated positively with delta epinephrine, heart
rate and METs (table 3). The mean maximum DBP (r=0.25,
p=0.05), and SBP (r=0.26, p=0.03) were also significantly
associated with delta FFAs. Interestingly, the mean time per test
(r=20.34, p=0.007) correlated negatively with the increment in
FFAs.
Stepwise linear regression model showed that baseline fasting
glucose, delta FFAs, delta epinephrine, MHR, and METs were
factors independently associated with the increment in serum
FGF21 levels after exercise (F=3.48; r
2=0.54, p,0.0001, table 5).
In a second model we evaluated the determinants of delta FFAs.
Interestingly, basal insulin, mean duration per exercise test, delta
epinephrine, and delta log FGF21 were factors independently
related to the increment in serum FFAs levels (F=3.4; r
2=0.44,
p=0.001, table 5).
Discussion
FGF21 plays an important role in carbohydrate and lipid
metabolism, and energy balance [1)]. However, in humans under
Table 3. Correlations of the DELTA log FGF21 (final-basal) with the delta and mean values of related parameters associated with
physical activity, lipolysis and adrenergic response (n=60).
Variable DELTA FGF21 DELTA FFA DELTA Leptin DELTA Epinephrine Mean RHR Mean MHR Mean METs
DELTA FGF21 - 0.35** 0.13 0.53** 0.43** 0.54** 0.40**
DELTA FFA - - 20.13 0.40** 0.05 0.22* 0.25*
DELTA Leptin - - - 0.11 0.02 20.35 20.19
DELTA Epinephrine - - - - 0.10 0.41** 0.18*
Mean RHR - - - - - 0.20 0.14
Mean MHR - - - - - - 0.58**
FGF21 was log-transformed before analysis. All the correlations were adjusted for BMI. FGF21=Fibroblast Growth Factor 21 (ng/l); RHR=Rest heart rate;
MHR=Maximum heart rate; METs=Metabolic equivalents; FFA=Free fatty acids;
*p,0.05;
**p,0.01.
doi:10.1371/journal.pone.0038022.t003
Table 4. Clinical and biochemical parameters stratified for tertiles of delta serum FGF21 (Final – Basal) levels.
Tertiles of delta FGF21 of Final – Basal levels (ng/l)
123
Variables Total ,88 ng/l 88–228 ng/l .228 ng/l p values
N 6 0 2 02 02 0 -
Age (yr) 24.063.7 24.463.4 24.163.3 23.564.4 0.75
Basal WC (cm) 74.668.0 75.466.3 74.468.7 74.169.0 0.87
Basal BMI (kg/m
2) 21.467.0 20.665.3 20.865.8 22.769.3 0.58
Basal Fat mass (%) 27.665.5 27.864.7 28.366.2 26.965.7 0.73
Delta FFAs (mg/dl) 0.16 (0.09–0.24) 0.10 (0.005–0.18) 0.16 (0.10–0.24) 0.20(0.13–0.38) 0.01
Delta Epi (pg/ml) 6.05 (3.0–9.7) 2.86 (1.3–6.6) 7.0 (5.1–9.7) 6.9 (4.1–10.4) 0.008
Delta Leptin (ng/ml) 20.30 (25.4–3.1) 20.74 (25.9–1.2) 0.66 (25.6–5.4) 0.94 (23.5–3.1) 0.32
Mean RHR (bpm) 89.5611.7 86.764.2 88.667.6 93.267.9 0.02
Mean MHR (bpm) 176.2612.8 165.267.5 181.3612.3 182.1610.5 ,0.0001
Mean METs 12.262.4 10.962.1 13.261.7 12.562.7 0.008
Mean Resting SBP 99.365.7 100.865.5 98.265.6 98.865.9 0.32
Mean Resting DBP 65.763.2 65.563.4 65.863.4 65.763.0 0.93
Mean Max SBP 127.1611.02 126.7610.6 131.2610.8 133.3610.5 0.05
Mean Max DBP 72.765.7 71.265.2 75.665.6 76.365.4 0.01
Data are expressed as mean6SD or as median (interquartil range). FGF21 was log-transformed before analysis. P values obtain from one-way ANOVA or Kruskall-Wallis
tests as appropriate. NS=not significant. WC=waist circumference; BMI=body mass index; FFAs=free fatty acids; Epi=epinephrine; BPM=beats per minute;
RHR=resting heart rest; MHR=maximum heart rate; METs=metabolic equivalents. SBP=systolic blood pressure; DBP=diastolic blood pressure. delta=Final – Basal
levels. Resting=value obtained before each test. Max=maximum value obtained during each test. Mean=sum of values/number of tests.
doi:10.1371/journal.pone.0038022.t004
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identified that FGF21 levels are associated with the amount of
physical activity recorded using a validated questionnaire [9].
Here, we investigate if a period of supervised exercise altered
serum FGF21 levels in healthy adults. Results showed that serum
FGF21 levels significant increased after two weeks of daily physical
activity, but no change was observed after a single bout of exercise.
The increment in FGF21 showed a positive correlation with the
changes in serum FFA levels. Interestingly, METs, RHR, MHR
and delta epinephrine (markers of adrenergic activation) correlated
positively with the increase in FGF21.
Exercise increases lipolysis through the agonist effect of
epinephrine on beta 3 adrenergic receptors in adipose tissue
[15–18]. The amount of exercise considered in our protocol
induced a significant adrenergic response measured clinically (with
heart rate and blood pressure) and biochemically (with epineph-
rine). The adrenergic response is greater in women who are not
physically fit. These characteristics allow us to evaluate with
certainty the acute and medium-term effects of exercise on FGF21
serum levels.
Baseline fasting glycemia, delta FFAs, epinephrine, heart rate
and METs were associated with an exercise –induced increment in
FGF21 levels. The FFA response may be the main signal for
increasing FGF21 concentrations. The FGF21 gene has a PPAR
alpha response element that is activated by the complex FFA/
PPAR alpha/RXR [19,20]. The central role of PPAR alpha
activation is demonstrated by the almost complete elimination of
the effects of fasting on FGF21 expression in the PPAR alpha
knockout mouse [21], and the increment of hormone in response
to an IV infusion of fatty acids [14]. However, in order to become
a biologically relevant signal for increasing the expression of the
FGF21 gene, supraphysiological concentrations of FFAs are
needed [22]. This phenomenon may explain the increased
FGF21 concentrations reported in prolonged fasting [3], lactation
[23], and growth hormone therapy [24], conditions associated
with remarkably high FFA plasma levels. The same observation
may explain the weak correlation observed between FGF21 and
baseline serum FFAs (r=0.12, p=0.03) reported in both our study
and by other groups [4,23]. Thus, it is likely that chronic
exposition to increased FFA concentrations may have a stronger
association with FGF21 serum levels than fasting FFA. This
proposal may explain the strong association reported between
serum FGF21 levels and liver fat content [25]. On the other hand,
another determinant of the change in FGF21 levels in our study
was baseline fasting glycemia. This association is explained by the
presence of a carbohydrate response element binding protein
(ChREBP) response element in the FGF21 gene [22]. Previous
reports have shown that fasting glycemia is associated with FGF21
serum levels [9,26]. Our report provides confirmatory evidence
and shows that the prominent role of glycemia continues under
conditions of stimulated lipolysis. The other predictors of the
change in FGF21 levels (i.e. epinephrine, heart rate and METs)
are markers of the exercise induced adrenergic response and the
subsequent increment of FFAs. The variables discussed above
determined more than 50% of the increment in FGF21 after two
weeks of physical activity. Thus, a large percentage of the
variability in the FGF21 response to exercise can be explained by
the variables evaluated here.
Exercise improves glucose disposal by increasing insulin action
and by activating the AMPK pathways, causing GLUT4
translocation to the muscle cell surface and glucose uptake [27].
The FGF21 response to exercise could be involved in the
beneficial effects of increased physical activity in lipid and
carbohydrate utilization, in healthy and obese individuals. The
increment in serum FGF21 may aim to decrease the level of FFAs
through the inhibition of lipolysis [28]. In addition, both chronic
exercise and FGF21 induce expression of the peroxisome
proliferator-activated receptor c coactivator protein-1a (PGC1al-
pha), a transcriptional coactivator protein that interacts with
several different DNA-binding proteins resulting in increased
gluconeogenesis, fatty acid oxidation, and ketogenesis [4,6,29].
These actions lower serum FFAs concentrations and may protect
against the ectopic deposit of lipids in the liver and the muscle.
Lipotoxicity plays a major role in the pathogenesis of the obesity-
related metabolic complications. This interpretation is in agree-
ment with the increased FGF21 levels reported in patients with the
Table 5. Multiple stepwise regression analysis of variables independently associated with the delta log serum FGF21 levels (model
1) and free fatty acids (model 2).
Model 1
Independent variables b Standardized b t p value
Basal Glucose 0.016 0.208 2.732 0.009
Delta FFA 1.018 0.340 2.823 0.007
Delta Epinephrine 13.88 0.269 2.248 0.030
Mean MHR 0.021 0.490 3.084 0.004
Mean METs 0.089 0.389 3.217 0.002
Model 2
Independent variables b Standardized b t p value
Insulin 20.016 20.376 22.24 0.03
Time of exercise 20.046 20.358 22.52 0.01
Delta Epinephrine 0.014 0.306 2.08 0.04
Delta FGF21 0.170 0.510 3.45 0.001
The analyses also included age, duration of exercise, creatinine, waist to hip ratio, fat percentage, body mass index, mean resting heart rate, systolic and diastolic blood
pressure, which were all excluded in the final models. FFAs=free fatty acids. MHR=maximum heart rate. Delta=Final – Basal levels. Parameters of model 1: F=3.48;
r
2=0.54, p,0.001. Parameters of model 2: F=3.4; r
2=0.44, p=0.001. Maximum=maximum value obtained during each test. Mean=sum of values/number of tests.
doi:10.1371/journal.pone.0038022.t005
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[8,9,26]. Probably, the increment of FGF21 is a mechanism to
counteract the chronic exposition of increased FFAs plasma levels
and lipotoxicity. Exercise may reinforce this compensatory
pathway. However, the FGF21 increment only happens after a
chronic stimulus capable of inducing adrenergic activation. A
single bout of intense exercise did not alter FGF21 serum levels. A
potential explanation for this finding is the increased insulin
response observed after a single session of exercise. Insulin inhibits
lipolysis and blocks the main mechanism by which exercise
stimulates FGF21 secretion (i.e. increased FFAs plasma levels).
Thus, increased FGF21serum levels may be an additional
mechanism by which exercise improves carbohydrate and lipid
metabolism in the medium term.
Some limitations of our study should be recognized. We cannot
fully control other potential sources of physical activity. We fully
relied on the adherence of the participants to our recommenda-
tions. However, the second evaluation with the questionnaire
suggests that participants considerably increased the kcal/day
consumed because of the study. In addition, the results may not be
applicable to men. Finally, we did not register the caloric
consumption during the study. However, no major changes in
BMI and body composition were observed.
In summary, serum FGF21 increased significantly after two
weeks of daily physical activity. This increment is related to clinical
and biochemical parameters of adrenergic response and serum
levels of FFAs.
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